ImmuCell Corp

Insider buying surge at ImmuCell signals confidence in its passive‑antibody biotech pipeline, with implications for investors, healthcare delivery, and reimbursement strategies.

Zero‑cost insider option exercises at ImmuCell signal confidence in rising milk‑derived antibody demand, hinting at potential upside for investors.